Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
24. Februar 2022 09:00 ET
|
Neovasc, Inc.
VANCOUVER, Feb. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday,...
Neovasc Announces German Reimbursement Renewal and Commercial Progress
08. Februar 2022 09:05 ET
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Feb. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the German Institute for the Hospital...
Independent Publication Reports Neovasc Reducer™ Demonstrates Cost Savings
04. Februar 2022 09:05 ET
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Feb. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of cost-effectiveness...
Neovasc Announces Complete Dismissal of Securities Class Action Complaint with Prejudice
02. Februar 2022 09:05 ET
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced the complete dismissal of the...
Neovasc Announces Publication Supporting the Neovasc Reducer™ Device
20. Januar 2022 09:05 ET
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled,...
Neovasc Announces Case Series of First U.S. Reducer Implants Published In Peer-Reviewed Journal
18. Januar 2022 09:05 ET
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Jan. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of a case series in the...
Neovasc to Participate in H.C. Wainwright BIOCONNECT Virtual Conference
06. Januar 2022 09:05 ET
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be...
Neovasc Announces First Patient Enrollment in COSIRA-II Trial
05. Januar 2022 09:05 ET
|
Neovasc, Inc.
COSIRA-II Trial Designed to Study the Neovasc Reducer™ for Patients with Refractory Angina VANCOUVER and MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc....
Neovasc to Participate in Sidoti December Virtual Microcap Conference
01. Dezember 2021 09:05 ET
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Dec. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that its management team will be...
Neovasc Reducer™ System Receives National Reimbursement in France
30. November 2021 09:40 ET
|
Neovasc, Inc.
First therapy to receive newly established French reimbursement designation VANCOUVER and MINNEAPOLIS, Nov. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the...